HINOVA PHARMACEUTICALS INC. Financials Hinova Pharmaceuticals Inc.
Equities
688302
CNE1000059F5
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.45 CNY | +0.26% |
|
+4.71% | -41.52% |
| Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,992 | 5,156 | 3,015 | - | - |
| Enterprise Value (EV) 1 | 3,992 | 5,156 | 3,015 | 3,015 | 3,015 |
| P/E ratio | -12.3 x | -17.5 x | -6.38 x | -24.5 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 23.2 x | 6.19 x | 2.72 x |
| EV / Revenue | - | - | 23.2 x | 6.19 x | 2.72 x |
| EV / EBITDA | - | -17.9 x | -6.64 x | -9.28 x | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | 3.77 x | 4.52 x | 8.98 x | - |
| Nbr of stocks (in thousands) | 99,016 | 99,016 | 99,016 | - | - |
| Reference price 2 | 40.32 | 52.07 | 30.45 | 30.45 | 30.45 |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 130 | 487 | 1,110 |
| EBITDA 1 | - | -287.7 | -454 | -325 | - |
| EBIT 1 | - | -294.4 | -459 | -331 | - |
| Operating Margin | - | - | -353.08% | -67.97% | - |
| Earnings before Tax (EBT) 1 | - | -294.4 | -459 | -331 | - |
| Net income 1 | -301.5 | -294.5 | -472.1 | -123.5 | - |
| Net margin | - | - | -363.15% | -25.37% | - |
| EPS 2 | -3.270 | -2.970 | -4.770 | -1.245 | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -22.3% | -20% | -66.9% | -44% | - |
| ROA (Net income/ Total Assets) | - | -18.2% | -62.3% | -77.2% | - |
| Assets 1 | - | 1,614 | 757.8 | 160 | - |
| Book Value Per Share 2 | - | 13.80 | 6.730 | 3.390 | - |
| Cash Flow per Share 2 | - | -2.580 | -4.880 | -3.770 | - |
| Capex 1 | - | 99.2 | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
30.45
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -41.52% | 418M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +49.05% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- 688302 Stock
- Financials Hinova Pharmaceuticals Inc.